ABVC BioPharma vs Scienture
ABVC and SCNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABVC and SCNX compare
Scienture is the larger company, worth 4.7 times as much as ABVC BioPharma ($119M against $25.6M).
ABVC BioPharma scores higher on the StockData Score (4 against 3 for Scienture), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABVC | SCNX |
|---|---|---|
| Size and price | ||
| Market cap | $25.6M | $119M |
| Share price | $0.960 | $2.90 |
| Change, 1 year | −66.8% | −83.7% |
| Change, 5 years | −97.1% | −99.8% |
| Beta (5Y) | 1.07 | 2.07 |
| Employees | 19 | 8 |
| StockData Score | ||
| Total score | 4 (better) | 3 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 2.0× | 1.9× (better) |
| Growth | ||
| Revenue growth, 5Y average | −9.3% (better) | −52.1% |
| Profitability | ||
| Return on equity | −31.2% (better) | −53.5% |
| Return on invested capital | −35.7% (better) | −47.3% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −34.5× | −13.1× (better) |
| Current ratio | 0.20 | 3.04 (better) |
| Altman Z-score | −4.82 | 0.22 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 4.1% | – |
| Held by insiders | 0.49% | 16.6% |
| Short interest, % of float | – | 0.34% |
Go deeper
- ABVC stock overview
- ABVC income statement
- ABVC valuation and score
- SCNX stock overview
- SCNX income statement
- SCNX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.